1Suzuki Y, Tsutsumi Y, Nakagawa M, et al. Osteoclast-like cells in an in vitro model of bone destruction by rheumatoid synovium[J]. Rheumatology(Oxford), 2001, 40: 673-682
2Pettit AR, Ji H, von Stechow D, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis[J]. Am J Pathol, 2001, 159:1689-1699
3Redlich K, Hayer S, Ricci R, et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction[J]. J Clin Invest, 2002, 110(10):1419-1427
4Yudoh K, Matsuno H, Osada R, et al. Decreased cellular activity and replicative capacity of osteoblastic cells isolated from the periarticular bone of rheumatoid arthritis patients compared with osteoarthritis patients[J]. Arthritis Rheum,2000, 43: 2178-2188
5Chen S, Guttridge DC, Tang E, et al. Suppression of tumor necrosis factor-mediated apoptosis by nuclear factor kappaB-independent bone morphogenetic protein/Smad signaling[J]. J Biol Chem, 2001, 276: 39259-39263
6Goldring SR. Pathogenesis of bone erosions in rheumatoid arthritis[J]. Curr Opin Rheumatol, 2002, 14: 406-410
7Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand[J]. Nature,1999, 402: 304-309
8Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis[J]. Arthritis Rheum, 2000, 43:259-269
9Mori H, Kitazawa R, Mizuki S, et al. RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse[J]. Histochem Cell Biol, 2002, 117:283-292
10Haynes DR, Barg E, Crotti TN, et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls[J]. Rheumatology(Oxford), 2003, 42:123-134
5HUNTER D J, SAMBROOK P N. Bone loss Ep idemiotogy of bone loss[J]. Arthritis Res,2000,2(6):441-445.
6HIRAYAMA T,DANKS L,SABOKBAR A, et al. Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis [J]. Rheumatology Oxford, 2002,41 (11):1232-1239.
7VALLEALA H, LAASONEN L, KO IVULA M K, et al. Two year randomized controlled trial of etidronate in rheumatoid arthritis:changes in serum aminoterminal telopep tides correlate with radiographic progression of disease[J]. J Rheurnatol,2003,30(3) :468-473.
8Banerjee AR,Jones JL,Birchall JP et al. Localization of matrix metalloproteinases 1 in cholesteatoma and deep meatal skin[J]. Otol Neurotol,2001,22(5):579-581.
9Lee ZH,Lee SE,Kim CW, etal. IL-lalpha stimulation ofosteoclast survival through the PI 3-kinase/Akt and ERK pathways[J]. J Biochem (Tokyo), 2002, 131(1): 161-166.
10Hotokezaka H, Sakai E, Ohara N,et al. Molecular analysis of RANKL-independent cell fusion of osteoclast-like cells in- duced by TNF-alpha, lipopolysaccharide, or peptidoglycan[ J]. J Cell Bio-chem, 2007, 101(1): 122-134.
